Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for six companies, including Chengyi Biotechnology, regarding compliance with capital structure and reverse mergers [1] - Chengyi Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with Jefferies, BofA Securities, and CICC as joint sponsors [1] - The CSRC requires Chengyi Biotechnology to clarify various aspects of its capital structure and compliance with foreign exchange management regulations, including shareholder registration and pricing of acquisitions [1][2] Group 2 - Chengyi Biotechnology is a clinical-stage global biotechnology company focused on developing next-generation oral small molecule drugs to address unmet medical needs in cardiovascular metabolic diseases and inflammatory diseases [3] - The company utilizes its proprietary TRANDD platform to create a product pipeline aimed at effective outcomes in weight management, metabolic-associated fatty liver disease, osteoarthritis pain, and other cardiovascular metabolic diseases [3]
新股消息 | 诚益生物拟港股上市 中国证监会要求补充说明股权架构搭建及返程并购的合规性等
智通财经网·2026-01-19 06:13